TY - JOUR
T1 - Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours
AU - Sponziello, Marialuisa
AU - Durante, Cosimo
AU - Boichard, Amelie
AU - Dima, Mariavittoria
AU - Puppin, Cinzia
AU - Verrienti, Antonella
AU - Tamburrano, Giulia
AU - Di Rocco, Giorgio
AU - Redler, Adriano
AU - Lacroix, Ludovic
AU - Bidart, Jean Michel
AU - Schlumberger, Martin
AU - Damante, Giuseppe
AU - Russo, Diego
AU - Filetti, Sebastiano
N1 - Funding Information:
The study was supported by research grants from The Umberto Di Mario Foundation and from the Banca d’Italia. It was also supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) (grant n. IG 10296 ) and Italian Government PRIN (grant numbers 200937N3ME_005 and 20093WAPYK_003).
PY - 2014/7/5
Y1 - 2014/7/5
N2 - Epigenetic control of gene expression plays a major influence in the development and progression of many cancer types. Aim of the present study was to investigate the expression of epigenetic regulators in a large cohort of medullary thyroid carcinomas (MTC), correlating the data with the clinical outcome and mutational status of the patients. Taqman Low Density Arrays (TLDAs) were used to analyze expression levels of several genes involved in the epigenetic control of transcription in a series of 54 MTCs. The patients cohort included 13 familial MTCs and 41 sporadic forms; 33 hosted a RET mutation and 13 a RAS somatic mutation. The expression profiling revealed in the more aggressive diseases (i.e. occurrence of metastases; persistent disease; disease-related death) a significant increase of EZH2 and SMYD3 gene expression. The increased levels of EZH2 and SMYD3 did not correlate significantly with mutational status of RET or RAS genes. Thus, the histone methyltransferases EZH2 and SMYD3 mRNA expression may represent useful prognostic biomarkers tailoring the most appropriate follow-up and timing of therapeutic approaches.
AB - Epigenetic control of gene expression plays a major influence in the development and progression of many cancer types. Aim of the present study was to investigate the expression of epigenetic regulators in a large cohort of medullary thyroid carcinomas (MTC), correlating the data with the clinical outcome and mutational status of the patients. Taqman Low Density Arrays (TLDAs) were used to analyze expression levels of several genes involved in the epigenetic control of transcription in a series of 54 MTCs. The patients cohort included 13 familial MTCs and 41 sporadic forms; 33 hosted a RET mutation and 13 a RAS somatic mutation. The expression profiling revealed in the more aggressive diseases (i.e. occurrence of metastases; persistent disease; disease-related death) a significant increase of EZH2 and SMYD3 gene expression. The increased levels of EZH2 and SMYD3 did not correlate significantly with mutational status of RET or RAS genes. Thus, the histone methyltransferases EZH2 and SMYD3 mRNA expression may represent useful prognostic biomarkers tailoring the most appropriate follow-up and timing of therapeutic approaches.
KW - Epigenetics
KW - Histone methylation
KW - Medullary thyroid cancer
KW - RAS
KW - RET
UR - http://www.scopus.com/inward/record.url?scp=84901292802&partnerID=8YFLogxK
U2 - 10.1016/j.mce.2014.04.016
DO - 10.1016/j.mce.2014.04.016
M3 - Article
C2 - 24813658
AN - SCOPUS:84901292802
SN - 0303-7207
VL - 392
SP - 8
EP - 13
JO - Molecular and Cellular Endocrinology
JF - Molecular and Cellular Endocrinology
IS - 1-2
ER -